Kurt M. Huber
Distinguished in Heart Attack

Kurt M. Huber

Vienna, AT 
Distinguished in Heart Attack
Vienna, AT 
OverviewLocationsClinical Research

Overview

Kurt Huber practices in Vienna, Austria. Mr. Huber is rated as a Distinguished expert by MediFind in the treatment of Heart Attack. His top areas of expertise are Heart Attack, Acute Coronary Syndrome, Cardiogenic Shock, Percutaneous Coronary Intervention (PCI), and Angioplasty.

His clinical research consists of co-authoring 598 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 208 articles in the study of Heart Attack.

Gender
Male

Locations

Vienna, Austria
Other Locations
Ottakring, Austria
Prater, 1020, Austria
Austria
Graz, Austria
Landesklinikum St. Pölten
Sankt Poelten, Austria

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)
A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)
Enrollment Status: Completed
Publish Date: October 21, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Prospective, Placebo-Controlled, Double-Blind, Randomized Study Evaluating the Efficacy of Non-Polymer-Based Coating With Two Different Rapamycin-Dosages for the Prevention of Restenosis After Percutaneous Coronary Interventions
A Prospective, Placebo-Controlled, Double-Blind, Randomized Study Evaluating the Efficacy of Non-Polymer-Based Coating With Two Different Rapamycin-Dosages for the Prevention of Restenosis After Percutaneous Coronary Interventions
Enrollment Status: Terminated
Publish Date: October 08, 2020
Intervention Type: Device
Study Phase: Phase 4
View 1 Less Clinical Trial

598 Total Publications

Assessment of precision medicine potential in diabetes mellitus: A meta-regression analysis of dose-dependent glycaemic control data from 44 randomised controlled trials.
Assessment of precision medicine potential in diabetes mellitus: A meta-regression analysis of dose-dependent glycaemic control data from 44 randomised controlled trials.
Journal: Diabetes, obesity & metabolism
Published: June 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Huber's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 41 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile